Author of

• 20155

  +

  P1.06 - Epidemiology/Primary Prevention/Tobacco Control and Cessation (ID 692)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Epidemiology/Primary Prevention/Tobacco Control and Cessation
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 22662

    +

    P1.06-018 - EGFR Mutations and ALK Gene Rearrangements: Changing Patterns of Molecular Testing in Brazil (ID 10068)

    09:30 - 16:00  |  Author(s): S. Palacio
    • Abstract

    Background:
    Lung cancer is the leading cause of cancer death worldwide. In Brazil, cancer is the second most common cause of death and there were an estimated 27,330 new cases of lung cancer in 2014. Targeted therapies have changed disease prognosis and current clinical guidelines advocate for testing all patients with advanced disease for EGFR mutations and ALK gene rearrangements. Access to this testing is often limited in the developing world. In the case of Brazil, there is limited data regarding the frequency of testing and the changes in patterns of testing overtime.
    
    Method:
    Observational, retrospective study involving practice patterns of over 2000 cancer physicians in Brazil. We obtained de-identified data from a commercial database which included 11,684 patients with non-small cell lung cancer treated between 2011 and 2016. We analyzed the frequency of EGFR mutation testing and ALK rearrangement testing.
    
    Result:
    11,684 patients were analyzed, of which all had stage IV lung adenocarcinoma. In the years ranging from 2011 to 2016 there was a significant increase in the frequency of testing for EGFR mutations overtime; from 13% in 2011 (287/2228) to 34% in 2012 (738/2142), 39% in 2013 (822/2092), 44% in 2014 (866/1972) to 53% in 2015 (1165/2184) and 58% in 2016 (626/1066). Testing for ALK rearrangements over that same time period also increased noticeably from no patients tested in 2011 and 2012, to 0.9% in 2013 (19/2092) 3% in 2014 (59/1972), 5% in 2015 (121/2184), 5% in 2016 (52/1066).
    
    Conclusion:
    To our knowledge this is the largest data analysis regarding changing practice patterns of molecular testing for lung adenocarcinoma over time in Brazil and Latin America. The frequency of testing for EGFR mutations and ALK gene rearrangement has increased over the last 5 years but is still below the current guidelines recommending that all patients with advanced disease be tested. Further understanding of the barriers to testing, will hopefully lead to national strategies for universal implementation of molecular testing.